We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$206M
Cap. Flow
+$79.9M
Cap. Flow %
10.7%
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16

Top Buys

1
ALKS icon
Alkermes
ALKS
+$15.6M
2
STAA icon
STAAR Surgical
STAA
+$15.2M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.8M
4
LNTH icon
Lantheus
LNTH
+$12.5M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$11.4M

Top Sells

1
AGN
Allergan plc
AGN
+$16.2M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.6M
3
NVRO
NEVRO CORP.
NVRO
+$12.9M
4
WMGI
Wright Medical Group Inc
WMGI
+$12.8M
5
ABBV icon
AbbVie
ABBV
+$11.7M

Sector Composition

1 Healthcare 46.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
26
Relmada Therapeutics
RLMD
$550M
$8.61M 1.15%
+220,724
New +$6.71M
AUPH icon
27
Aurinia Pharmaceuticals
AUPH
$2.05B
$8.1M 1.09%
+400,000
New +$3.68M
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
$7.77M 1.04%
1,029,012
-2,073,661
-67% -$11M
XCUR icon
29
Exicure
XCUR
$10.7M
$7.74M 1.04%
18,052
+2,639
+17% +$1.08M
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$7.03M 0.94%
134,937
-3,100
-2% -$142K
ICUI icon
31
ICU Medical
ICUI
$3.94B
$5.61M 0.75%
30,000
– –
LMNX
32
DELISTED
Luminex Corp
LMNX
$4.81M 0.64%
+207,553
New +$4.28M
ALKS icon
33
CALL
Alkermes
ALKS
$8.79B
$4.08M 0.55%
+200,000
New +$3.98M
SSKN
34
DELISTED
Strata Skin Sciences
SSKN
$3.83M 0.51%
183,937
-107,755
-37% -$2.45M
ANAB icon
35
AnaptysBio
ANAB
$1.72B
$3.6M 0.48%
+221,600
New +$5.24M
ACRS icon
36
Aclaris Therapeutics
ACRS
$793M
$3.57M 0.48%
1,888,039
+268,039
+17% +$444K
VTRS icon
37
Viatris
VTRS
$20.1B
$3.02M 0.4%
+150,000
New +$2.79M
HRTX icon
38
Heron Therapeutics
HRTX
$89.1M
$2.11M 0.28%
89,730
-8,507
-9% -$188K
SCYX icon
39
SCYNEXIS
SCYX
$42.4M
$1.82M 0.24%
+25,000
New +$2.06M
PTN
40
Palatin Technologies
PTN
$16.2M
$819K 0.11%
838
– –
ABBV icon
41
AbbVie
ABBV
$450B
– –
-154,500
Closed -$11.7M
ADMA icon
42
ADMA Biologics
ADMA
$2.02B
– –
-505,900
Closed -$2.25M
CPRX icon
43
Catalyst Pharmaceutical
CPRX
– –
-880,303
Closed -$4.67M
HRTX icon
44
CALL
Heron Therapeutics
HRTX
$89.1M
– –
-100,000
Closed -$1.85M
SIBN icon
45
SI-BONE Inc
SIBN
$771M
– –
-223,291
Closed -$3.95M
TVTX icon
46
Travere Therapeutics
TVTX
$5.27B
– –
-610,414
Closed -$7.08M
XGN icon
47
Exagen
XGN
$106M
– –
-311,284
Closed -$4.82M
NVRO
48
DELISTED
NEVRO CORP.
NVRO
– –
-150,510
Closed -$12.9M
MRTX
49
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-200,000
Closed -$15.6M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-177,016
Closed -$8.59M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Broadfin Capital deployed $79.9M of net new capital in Q4 2019, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 54% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $13.6M trimmed.

  • Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
  • Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
  • Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
  • Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
  • Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
  • Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
  • Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.